Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Key facts

Sponsor

ZevraDenmark

Principal Investigator

Mazen M Dimachkie, M.D

University of Kansas Medical Center

Intervention

Arimoclomol(drug)

Enrollment

121 enrolled

Eligibility

45 years · All sexes

Timeline

2019 – 2021

Study locations (12)

• Phoenix Neurological Associates, Phoenix, Arizona, United States
• University of California, Irvine, California, United States
• University of Colorado School of Medicine, Aurora, Colorado, United States
• University of Kansas Medical Center, Kansas City, Kansas, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• Brigham and Women's Hospital, Boston, Massachusetts, United States
• University of Rochester, Rochester, New York, United States
• The Ohio State University, Columbus, Ohio, United States
• Nerve and Muscle Center of Texas, Houston, Texas, United States
• University of Utah, Salt Lake City, Utah, United States
• University of Virginia, Charlottesville, Virginia, United States
• University College of London, London, United Kingdom

Collaborators

University of Kansas Medical Center · University College, London

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Inclusion body myositis

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT07072676
  The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
  LMU Klinikum
• RECRUITINGPHASE2NCT06536166
  Ruxolitinib Treatment in Inclusion Body Myositis
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06450886
  Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
  Abcuro, Inc.
• RECRUITINGEARLY PHASE1NCT06479863
  Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
  Austin Neuromuscular Center
• ACTIVE NOT RECRUITINGNCT06153108
  Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
  University of Kansas Medical Center
• ACTIVE NOT RECRUITINGPHASE3NCT04789070
  Phase III Trial of Sirolimus in IBM
  University of Kansas Medical Center
• ACTIVE NOT RECRUITINGNCT05046821
  Sporadic Inclusion Body Myositis Natural History Study
  University of California, Irvine

See all trials for Inclusion body myositis →